Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 14, 2026, 1:49 AM EDT
Completed No phase listed Observational

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590
View directory record Official record
Conditions
Primary Hyperoxaluria Type 3
Interventions
Not listed
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
2 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

NCT05394519
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes Mellitus
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Concord, California • Escondido, California • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

NCT06534411
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
54
States / cities
Pelham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

NCT00982228
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
59
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Not yet recruiting Phase 3 Interventional

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

NCT07830732
View directory record Official record
Conditions
Haemophilia A
Interventions
Denecimig
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Iowa City, Iowa • Metairie, Louisiana • Minneapolis, Minnesota + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 4 Interventional

Comparison of Glycemic Control Achieved With 2 Different Needles

NCT00572052
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
NovoFine® needle 6 mm, Ultra-Fine needle 12.7 mm
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Walnut Creek, California • Berlin, New Jersey • Lawrenceville, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

NCT02541942
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 14, 2026, 1:49 AM EDT
Enrolling by invitation No phase listed Observational

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

NCT05872022
View directory record Official record
Conditions
Pregnancy, Obesity, Overweight
Interventions
No Intervention
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Timeline
2023 – 2032
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 3 Interventional

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

NCT00427154
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
rosiglitazone, inhaled human insulin, metformin, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
103
States / cities
Hueytown, Alabama • Ozark, Alabama • Tuscaloosa, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

NCT01179048
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
9,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
125
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225
View directory record Official record
Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
Etavopivat
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Ocala, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated No phase listed Observational

Emory Latino Diabetes Education Program

NCT00793884
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

NCT04987489
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Etavopivat tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Cerritos, California • Los Angeles, California • Oakland, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Results available

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

NCT00634842
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
66
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A

NCT01205724
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Iowa City, Iowa • Lexington, Kentucky • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04460885
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 4 Interventional

NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

NCT00095446
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

NCT01636843
View directory record Official record
Conditions
Inflammation, Rheumatoid Arthritis
Interventions
NNC0109-0012, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Huntington Beach, California • La Mesa, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

NCT05514535
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
145
States / cities
Sheffield, Alabama • Glendale, Arizona • Mesa, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 14, 2026, 1:49 AM EDT